Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 49.6
(1.14%)
EUR 49.6
(1.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 245.81 Million EUR | -12.17% |
| 2022 | 281.48 Million EUR | 37.96% |
| 2021 | 204.71 Million EUR | 109.46% |
| 2020 | 93.27 Million EUR | 58.83% |
| 2019 | 61.21 Million EUR | 106.82% |
| 2018 | 29.41 Million EUR | -1.85% |
| 2017 | 30.58 Million EUR | -24.63% |
| 2016 | 35.75 Million EUR | 21.95% |
| 2015 | 32.65 Million EUR | -12.03% |
| 2014 | 36.81 Million EUR | 13.44% |
| 2013 | 35.39 Million EUR | 18.4% |
| 2012 | 28.33 Million EUR | 6.6% |
| 2011 | 26.01 Million EUR | -16.58% |
| 2010 | 31.05 Million EUR | 16.17% |
| 2009 | 28.12 Million EUR | -14.34% |
| 2008 | 30.68 Million EUR | 86.06% |
| 2007 | 16.78 Million EUR | 554.68% |
| 2006 | 5.1 Million EUR | -100.0% |
| 2005 | 421.53 Billion EUR | 24321.68% |
| 2004 | 1.72 Billion EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 44.28 Million EUR | 72.06% |
| 2024 Q1 | 25.88 Million EUR | -64.8% |
| 2023 FY | - EUR | -12.17% |
| 2023 Q2 | 31.07 Million EUR | -53.56% |
| 2023 Q1 | 66.91 Million EUR | -37.27% |
| 2023 Q4 | 73.12 Million EUR | -1.83% |
| 2023 Q3 | 74.48 Million EUR | 139.68% |
| 2022 Q4 | 106.67 Million EUR | 86.73% |
| 2022 FY | - EUR | 37.96% |
| 2022 Q1 | 74.3 Million EUR | 17.56% |
| 2022 Q2 | 41.51 Million EUR | -44.14% |
| 2022 Q3 | 57.13 Million EUR | 37.63% |
| 2021 Q4 | 63.21 Million EUR | -3.41% |
| 2021 FY | - EUR | 109.46% |
| 2021 Q1 | 34.77 Million EUR | 28.87% |
| 2021 Q2 | 39.26 Million EUR | 12.91% |
| 2021 Q3 | 65.44 Million EUR | 66.69% |
| 2020 Q3 | 27.35 Million EUR | 22.37% |
| 2020 FY | - EUR | 58.83% |
| 2020 Q1 | 20.08 Million EUR | 49.85% |
| 2020 Q2 | 22.35 Million EUR | 11.3% |
| 2020 Q4 | 26.98 Million EUR | -1.35% |
| 2019 Q2 | 14.52 Million EUR | 21.23% |
| 2019 Q4 | 13.4 Million EUR | -36.27% |
| 2019 FY | - EUR | 106.82% |
| 2019 Q1 | 11.97 Million EUR | 245.36% |
| 2019 Q3 | 21.02 Million EUR | 44.82% |
| 2018 Q4 | 3.46 Million EUR | -72.57% |
| 2018 Q3 | 12.64 Million EUR | 300.28% |
| 2018 Q2 | 3.15 Million EUR | -68.92% |
| 2018 Q1 | 10.16 Million EUR | 242.11% |
| 2018 FY | - EUR | -1.85% |
| 2017 FY | - EUR | -24.63% |
| 2017 Q4 | 2.97 Million EUR | -11.23% |
| 2017 Q3 | 3.34 Million EUR | -75.27% |
| 2017 Q2 | 13.53 Million EUR | 33.14% |
| 2017 Q1 | 10.16 Million EUR | 23.48% |
| 2016 Q2 | 12.06 Million EUR | -8.09% |
| 2016 Q1 | 13.12 Million EUR | 94.69% |
| 2016 FY | - EUR | 21.95% |
| 2016 Q3 | 6.4 Million EUR | -46.92% |
| 2016 Q4 | 8.23 Million EUR | 28.55% |
| 2015 Q1 | 9.67 Million EUR | 30.93% |
| 2015 FY | - EUR | -12.03% |
| 2015 Q4 | 6.74 Million EUR | 11.7% |
| 2015 Q3 | 6.03 Million EUR | -40.86% |
| 2015 Q2 | 10.2 Million EUR | 5.5% |
| 2014 Q4 | 7.38 Million EUR | -9.13% |
| 2014 FY | - EUR | 13.44% |
| 2014 Q1 | 9.16 Million EUR | 31.2% |
| 2014 Q2 | 12.13 Million EUR | 32.49% |
| 2014 Q3 | 8.13 Million EUR | -33.03% |
| 2013 Q4 | 6.98 Million EUR | -1.3% |
| 2013 FY | - EUR | 18.4% |
| 2013 Q1 | 7.69 Million EUR | -30.86% |
| 2013 Q2 | 10.93 Million EUR | 42.08% |
| 2013 Q3 | 7.07 Million EUR | -35.27% |
| 2012 Q4 | 11.12 Million EUR | 97.02% |
| 2012 FY | - EUR | 6.6% |
| 2012 Q1 | 7.03 Million EUR | -37.06% |
| 2012 Q3 | 5.64 Million EUR | -42.93% |
| 2012 Q2 | 9.89 Million EUR | 40.62% |
| 2011 Q4 | 11.17 Million EUR | 130.82% |
| 2011 Q2 | 10.43 Million EUR | 59.71% |
| 2011 Q3 | 4.84 Million EUR | -53.58% |
| 2011 FY | - EUR | -16.58% |
| 2011 Q1 | 6.53 Million EUR | 1058.16% |
| 2010 Q3 | 7.94 Million EUR | -48.53% |
| 2010 Q1 | 7.13 Million EUR | 0.0% |
| 2010 Q4 | 564 Thousand EUR | -92.9% |
| 2010 FY | - EUR | 16.17% |
| 2010 Q2 | 15.43 Million EUR | 116.24% |
| 2009 FY | - EUR | -14.34% |
| 2008 FY | - EUR | 86.06% |
| 2007 FY | - EUR | 554.68% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | - EUR | 24321.68% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Atrys Health, S.A. | 31.91 Million EUR | -670.233% |
| Biotechnologies Assets SA | 5.09 Million EUR | -4720.838% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 5644.601% |
| Pharma Mar, S.A. | 4.54 Million EUR | -5303.649% |